论文信息 - Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). - 字舞流文

Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).

Juswinder Singh | T. Kipps | J. Gabrilove | S. O'brien | Jennifer R. Brown | D. Mahadevan | B. Silver | J. Sweetenham | J. Foran | K. Kelly | P. Barr | E. Evans | W. Westlin | J. Sharman | S. Witowski | M. Schreeder | K. Stiede | W. Harb | Heather Lounsbury | Shuo Ma | H. Lounsbury